ORIC Pharmaceuticals Statistics
Total Valuation
ORIC has a market cap or net worth of $641.23 million. The enterprise value is $392.07 million.
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ORIC has 70.54 million shares outstanding. The number of shares has increased by 48.28% in one year.
| Current Share Class | 70.54M |
| Shares Outstanding | 70.54M |
| Shares Change (YoY) | +48.28% |
| Shares Change (QoQ) | +4.45% |
| Owned by Insiders (%) | 1.54% |
| Owned by Institutions (%) | 66.23% |
| Float | 42.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.12 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.08, with a Debt / Equity ratio of 0.03.
| Current Ratio | 15.08 |
| Quick Ratio | 14.66 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -38.79% and return on invested capital (ROIC) is -26.41%.
| Return on Equity (ROE) | -38.79% |
| Return on Assets (ROA) | -25.20% |
| Return on Capital (ROIC) | -26.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.11M |
| Employee Count | 100 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.46% in the last 52 weeks. The beta is 1.12, so ORIC's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | +34.46% |
| 50-Day Moving Average | 9.70 |
| 200-Day Moving Average | 10.19 |
| Relative Strength Index (RSI) | 52.97 |
| Average Volume (20 Days) | 427,965 |
Short Selling Information
The latest short interest is 12.00 million, so 17.01% of the outstanding shares have been sold short.
| Short Interest | 12.00M |
| Short Previous Month | 12.26M |
| Short % of Shares Out | 17.01% |
| Short % of Float | 28.09% |
| Short Ratio (days to cover) | 25.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -125.12M |
| Pretax Income | -101.76M |
| Net Income | -110.78M |
| EBITDA | -124.06M |
| EBIT | -125.12M |
| Earnings Per Share (EPS) | -$1.75 |
Full Income StatementBalance Sheet
The company has $286.41 million in cash and $9.74 million in debt, giving a net cash position of $276.67 million or $3.92 per share.
| Cash & Cash Equivalents | 286.41M |
| Total Debt | 9.74M |
| Net Cash | 276.67M |
| Net Cash Per Share | $3.92 |
| Equity (Book Value) | 302.40M |
| Book Value Per Share | 4.47 |
| Working Capital | 275.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$99.73 million and capital expenditures -$685,000, giving a free cash flow of -$100.41 million.
| Operating Cash Flow | -99.73M |
| Capital Expenditures | -685,000 |
| Free Cash Flow | -100.41M |
| FCF Per Share | -$1.42 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |